Pulse Biosciences appoints Liane Teplitsky COO; expands Dr. Kenigsberg as full-time CMO

PULSE BIOSCIENCES, INC.

Liane Teplitsky named COO effective April 8, 2026; oversees Clinical, Regulatory, Quality, Commercial functions.
Received inducement award: 700,000 stock options ($19.06) and 200,000 RSUs; vesting tied to market cap and revenue milestones.
Dr. David Kenigsberg expands to full-time Chief Medical Officer, continues active practice; will lead IDE pivotal study for nPulse catheter.
Two other new employees granted inducement options for 7,700 shares total at $19.06, time-vesting over four years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.